Delcath: Fundamentals Intact, Despite Share Price Weakness

2026-03-02 15:42:56 ET

Delcath Systems, Inc. ( DCTH ) offers a liver-directed chemotherapy system, which is currently used to treat metastatic uveal melanoma patients. The business has been negatively impacted by pricing pressure and seasonality in recent quarters but is generally progressing. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. There should also be tailwinds from clinical data demonstrating PHP's efficacy in combination with immunotherapies....

Read the full article on Seeking Alpha

For further details see: